The oral presentation is titled “ The RAS:PI3Ka breaker BBO-10203 inhibits PI3Ka/AKT activity in HER2AMP models through non-canonical RAS signaling blockade .” A copy of the presentation will be ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results